On International Biotechnology Day, New Medicines Cross from Lab to Clinic

Every June 16, the world marks International Biotechnology Day, recognizing the scientific breakthroughs that have reshaped medicine, agriculture, environmental science, and industry. The date traces back to the 1980 Supreme Court decision in Diamond v. Chakrabarty, which established that a genetically engineered organism could be patented and helped lay the legal foundation for the modern biotechnology industry.

More than four decades later, biotechnology is entering a new phase. The question is no longer whether scientists can edit genes, engineer cells, or develop highly targeted therapies. The question is how quickly those discoveries can reach patients. In 2026, the clearest trend across the sector is that new medicines are crossing from the laboratory into the clinic and, increasingly, into commercial use.

The Scientist Who Helped Change Biology

Much of that progress traces back to work begun decades earlier. While studying maize, Barbara McClintock discovered that segments of DNA could move within the genome, the transposable elements she called “jumping genes.” Her findings challenged long-held assumptions about heredity and gene regulation and ultimately reshaped how scientists understood the genome itself.

In 1983, she received the Nobel Prize in Physiology or Medicine, becoming the first woman to receive the award as its sole recipient. The foundation of modern gene-based medicine rests on the principle she uncovered. DNA is not a fixed script. It is dynamic, adaptable, and capable of change.

Regulators Are Accelerating the Path

Policy is increasingly moving alongside science.

On June 2, 2026, the FDA issued draft guidance intended to help developers bring gene therapies to patients more efficiently by allowing companies to leverage existing scientific and regulatory knowledge rather than rebuilding the evidence base for every new therapy from scratch.

The guidance reflects a broader shift across global regulatory agencies. As scientific understanding improves, regulators are looking for ways to shorten the distance between promising data and patient access, particularly for serious and rare diseases.

Where the Sector Stands Today

Across biotechnology, companies now occupy different stages of that journey. Some have already reached commercialization. Others are approaching pivotal clinical milestones. Still others remain in the earliest stages of development.

The companies below run from those already selling approved medicines to those still working toward their first human trials.

• CRISPR Therapeutics (CRSP): Commercial-stage gene editing. With partner Vertex, it markets Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta thalassemia. Casgevy generated $43 million in revenue in the first quarter of 2026, with more than 500 patients having begun treatment globally. The company is also advancing in vivo liver-editing programs and a new SyNTase editing platform, and ended the quarter with about $2.4 billion in cash.
• TG Therapeutics (TGTX): Commercial-stage and profitable. Its approved anti-CD20 antibody Briumvi treats relapsing multiple sclerosis. U.S. net product revenue reached about $195 million in the first quarter of 2026, up roughly 63% from a year earlier, and the company raised full-year guidance to $885 to $900 million while posting net income near $20 million. It held about $573 million in cash, with a subcutaneous version in Phase 3 and data expected around year-end.
• Intellia Therapeutics (NTLA): Clinical-stage, in vivo gene editing. Its candidate lonvo-z delivered the first positive Phase 3 result for an in vivo CRISPR therapy, an 87% reduction in hereditary angioedema attacks versus placebo, published in the New England Journal of Medicine in June. A rolling FDA submission began in April, and the company anticipates a U.S. launch in the first half of 2027. It held about $517 million in cash at quarter-end, with an April stock sale adding roughly $207 million, funding operations at least into 2028.
• Beam Therapeutics (BEAM): Clinical-stage base editing, which changes a single DNA letter without cutting the strand. Its lead cell therapy risto-cel for sickle cell was published in the New England Journal of Medicine, and a second program for alpha-1 antitrypsin deficiency is headed into a pivotal cohort the company expects to begin in the second half of 2026 under an accelerated pathway. It ended the quarter with about $1.2 billion in cash and runway into mid-2029.
• Taysha Gene Therapies (TSHA): Clinical-stage AAV gene therapy for monogenic diseases of the central nervous system. Its lead candidate TSHA-102 targets Rett syndrome. The company has reaffirmed an FDA-aligned path that could support a filing based on a six-month interim analysis of its REVEAL pivotal trial, with dosing in its two trials expected to finish in the second quarter of 2026. It held about $277 million in cash, funding operations into 2028.
• Metagenomi (MGX): The smallest and earliest-stage name here, a micro-cap in vivo genome-editing company built on metagenomics to mine novel CRISPR tools. Its lead program MGX-001 targets hemophilia A, with an IND submission planned for the fourth quarter of 2026 and first-in-human studies anticipated in 2027. It held $140.2 million in cash at the end of the first quarter of 2026, with runway through the fourth quarter of 2027.

Barbara McClintock’s discovery began as a scientific observation in a cornfield. Today, the technologies built on that insight are treating patients, extending lives, and creating entirely new approaches to medicine. On International Biotechnology Day, the industry’s progress is measured not only in discoveries, but in the growing number of therapies making the journey from the laboratory to the people who need them most.

This article is for informational purposes only and does not constitute investment advice or a recommendation regarding any security. The companies discussed are clinical and commercial-stage biotechnology firms whose programs carry significant regulatory, clinical, and financial risk, including the possibility of delay, non-approval, or commercial failure. Past performance does not indicate future results.